Clinical study of hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites
LI Guang-qing
MU Tie-jun
Abstract：[ABSTRACT]Objective:To evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer patients with malignant ascites.Methods: Totally 49 ovarian cancer patients were enrolled in this study from June 2011 to July 2014. A total of 25 cases in treatment group were given with HIPEC combined with cisplatin, and 24 patients were underwent intraperitoneal chemotherapy as a control group. Each patient in treatment group and control group had received six times chemotherapy during three weeks, twice one week. Changes of response rate, quality of life (KPS score) and the side effects were evaluated.Results: The response rate and improvement rate in KPS score were 84.0% and 84.0% respectively in treatment group, which showed higher than those in the control group (54.2% and 45.8%) with statistical signiifcance (P < 0.05). No severe side effect was observed during treatment.Conclusion:HIPEC is a feasible and safe treatment for ovarian carcinoma patients with malignant ascites, which can improve the short-term efifcacy and quality of life.
Keywords：Hyperthermic intraperitoneal chemotherapyOvarian cancerAscites
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 334-336,337 )